The 503A facilities are also producing compounded semaglutide and tirzepatide for hundreds of thousands of patients.

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure ...

Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and obese or overweight people over 176 weeks; shares rose modestly after ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

Findings at week 176 demonstrated that among prediabetic patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free. Detailed results were ...